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0929-6441/ª 2014, Elsevier Taiwan LLBackground: Uterine myomas (fibroids) are benign tumors of the uterus. Myomectomy, the sur-
gical removal of myoma, is an important treatment option. The major complication associated
with myomectomy is excessive bleeding. Many interventions have been used to reduce
bleeding during myomectomy. Misoprostol produces uterine contraction, thereby reducing
blood supply to the myometrium and in the myoma; it can be used as an alternative to uterine
artery occlusion or paracervical tourniquet to reduce blood flow during myomectomy. The
Color Doppler Misoprostol Response Study (CDMRS) is a study planned to assess the vascularity
of the myoma in patients with fibroid uterus and note the changes after misoprostol adminis-
tration.
Materials and methods: A baseline study of all the patients was done prior to insertion of mis-
oprostol or placebo, and the largest selected fibroid in the patients with uterine fibroids was
evaluated for its volume and perfusion by Doppler ultrasound. The resistive index (RI) was
measured prior to and after administration of 800 mg misoprostol (4 tablets) per rectal inser-
tion, after 20 minutes, and reevaluated 40 minutes postinsertion.
Results: Results from a t-test shows that the use of misoprostol significantly reduces the
volume of fibroid from 0e20 minutes by t0e20 [mean differenceZ 40.3 cm
3, confidence interval
(CI) 30.6e49.9, pZ 0.000) and t20e40 (mean differenceZ 36.2 cm
3, 95% CI 30.741.6 cm3,
pZ 0.000). In the control group receiving four tablets of placebo no significant difference was
noted in volume of the fibroid. Likewise, when we compared the RIs at different timings, the re-
sults were again in favor of misoprostol because the blood flow of myomas was substantially
reduced. The RI increased from t0e20 (mean difference Z 0.26, 95% CI 0.16 cm
3e0.38 cm3,
pZ 0.000) and t20-40 (mean differenceZ 0.08, 95% CI 0.330.04 cm3, pZ 0.000). In the control
group receiving four tablets of placebo, no significant difference was noted in perfusion of the
fibroid.clare no conflicts of interest. No funding was provided by any organization and no financial interests
nuscript.
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Color Doppler Misoprostol Response Study 79Fig. 1 Comparison of the change o
misoprostol administration.Conclusion: In conclusion, we suggest that all patients scheduled for myomectomy have prior
CDMRS to evaluate the degree of vascularity and to assess if they have an appropriate response
tomisoprostol administered rectally, so that there isminimal or no blood loss during surgery. This
preoperative assessment will decrease physician apprehension, with less intraoperative blood
loss and morbidity.
ª 2014, Elsevier Taiwan LLC and the Chinese Taipei Society of Ultrasound in Medicine.
Open access under CC BY-NC-ND license.Introduction
Uterine myomas (fibroids) are benign tumors of the uterus.
Myomectomy, the surgical removal of myoma, is an
important treatment option, especially for women who
wish to preserve their uteri. The major problem with
myomectomy is excessive bleeding, which can be life
threatening and prolong hospital stay. Many interventions
have been used to reduce bleeding during myomectomy.
The effective ones include the use of tourniquets, vaso-
pressin, chemical dissection, misoprostol, bupivacaine plus
epinephrine, and tranexamic acid [1].
Mifepristone (the abortion pill) also has been shown to
shrink uterine fibroids and improve quality of life [2].
Misoprostol, which is a prostaglandin analogue, is now
being widely used in the prevention and treatment of
postpartum hemorrhage as well as to induce birth or
abortion [3]. By contracting the myometrial muscles,
misoprostol has been shown to reduce the uterine artery
blood flow [4]. This has been shown in Fig. 1 (A and B).
In vitro studies have shown that prostaglandins have a
vasoconstrictive effect [5].
Previous studies have shown that uterine artery blood
flow to the myometrium is increased in patients with
myoma [6].
Uterine artery occlusion techniques developed as an
alternative to the hysterectomy or myomectomy, and are
successfully used in most myoma uteri cases [7,8]. Although
a temporary effect, misoprostol can reduce blood flow in
the myoma, and therefore can be used as an alternative to
uterine artery occlusion or other invasive techniques to
reduce blood flow during myomectomy [9].
The purpose of our Color Doppler Misoprostol Response
Study (CDMRS) was to observe changes in vascularity andf blood flow in the myoma on Coperfusion of fibroids and the surrounding myometrium
following misoprostol per rectal administration (Fig. 2).Materials and methods
To undertake this study, the ethical approval was taken
from the Ethical Review Board of the Ultrasound Society of
Pakistan (Fig. 3).
The study was conducted at the Clinic/Institute of Ultra-
sound Imaging, Karachi, Pakistan from March 2009 to
November 2011.Ourcenter is affiliatedwithThomasJefferson
University Hospital, Philadelphia, PA, USA, and provides ser-
vices to almost 25,000 patients per year. Ultrasound of almost
every part of the body is done at our center with the facili-
tation of convex, linear, transvaginal, and three-dimensional
probes. The procedures are being carried out by ultrasonog-
rapher specialists and the machine used for this work was
Toshiba Xario SSA-660Awith a 3.5MHz standard convex probe.
All premenopausal women (age 20e40 years) having fi-
broids not less than 5 cm in diameter were included in the
study. The patients were evaluated during the follicular
phase of the menstrual cycle Day 8 to decrease the chances
of ambiguity regarding endometrial thickness and general
vascularity. Written informed consent was obtained from
those who wished to participate in the study. Patients who
had a body mass index greater than 30, a known allergy to
misoprostol, hypertension, cardiac or pulmonary disease,
or fibroids smaller than 5 cm in diameter were excluded
from the study. We recruited 100 patients during the study
period, which fulfilled the inclusion criteria, and who
agreed to participate in the study.
This was a double-blind randomized trial. Every patient
filled in baseline information prior to the procedure andlor Doppler Misoprostol Response Study (A) before and (B) after
Fig. 2 Comparison of the change in spectral Doppler of the blood flow in the myoma (A) before and (B) after misoprostol
administration.
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adequately measure uterine size in women with a large
uterus. We then divided the patients into two groups. The
principal investigator along with the co-investigators per-
formed the ultrasound prior to and after administering
misoprostol. The patients in the study group (n1Z 50) were
given 800 mg misoprostol (4 tablets) rectally and those in
the control group (n2 Z 50) received placebo (inert tablet
in the same color and shape).
Myoma volume was expressed in cm3 and was calculated
according to the formula: length (cm)  depth
(cm)  width (cm)  0.5. If more than one myoma was
found in the pelvis, the largest one was examined and the
site localized by its distance from the endometrium and the
serosa.
The myoma vascularization and that of the surrounding
myometrium was visualized using the color Doppler tech-
nique. Blood flow velocity waveforms were obtained by
placing the Doppler gate over the maximum color areas and
activating the pulsed Doppler function at that marked site.
The vessel was measured after confirming the depth (same
depth of vessel from the upper margin) and the angle
correction prior to and after insertion. Resistive index (RI)
of the myoma vascularization was measured prior to and
after 800 mg misoprostol (4 tablets) per rectal insertion,
after 20 minutes, and again re-evaluated 40 minutes after
insertion. All patients were followed up the next day to
report any side effects.
Statistical analysis
We obtained frequencies of categorical variables, and for
continuous variables mean and standard deviation were
calculated. To determine whether misoprostol administra-
tion can change the volume of fibroids and level of RI at
different time intervals, we used the paired t-test. The
values were compared as (t0 vs. t20) and (t20 vs. t40) at 0.05
level of significance. Data analysis was carried out using
SPSS 19.0 (IBM, Armonk, NY, USA).Results
The maternal demographic information along with the
descriptive statistics, 95% confidence interval (CI) of vol-
ume of fibroid, and RI at different time intervals wasanalyzed. The average age of the women in the study group
and in the control group was 36.04  5.17 years and
36.1  5.50 years, respectively. There were 6% primiparous
and 47% multiparous women in both the groups.
Results from the t-test shows that the use of misoprostol
significantly reduces the volume of fibroid from 0 minutes
to 20 minutes by t0e20 (mean differenceZ 40.3 cm
3, 95% CI
30.6e49.9, p Z 0.000) and t20e40 (mean
difference Z 36.2 cm3, 95% CI 30.7e41.6 cm3, pZ 0.000).
In the control group receiving four tablets of placebo, no
significant difference was noted in the volume of the
fibroid.
Likewise, when we compared the RIs at different times,
the results were again in favor of misoprostol because they
significantly reduced the blood flow of myomas. The RI
increased from t0e20 (mean difference Z 0.26, 95% CI
0.16e0.38 cm3, p Z 0.000) and t20e40 (mean
difference Z 0.08, 95% CI 0.33 cm3e0.04 cm3, pZ 0.000).
In the control group receiving four tablets of placebo, no
significant difference was noted in perfusion of the fibroid.
It was observed that 27 of the patients had absent flow
within the fibroid at 20 minutes and 41 patients were found
to have absent flow at 40 minutes (Tables 1 and 2).
Discussion
The standard treatment for symptomatic myomas is hys-
terectomy for women who have completed their families,
and myomectomy for women who wish to preserve fertility.
Myomectomy can be accomplished by laparotomy, lapa-
roscopy, or hysteroscopy.
Massive blood loss associated with the dissection of huge
fibroids renders myomectomy a more technically chal-
lenging procedure than hysterectomy. Transfusion is
required in up to 20% of cases following abdominal myo-
mectomy; in 2% of cases, there is a need for conversion of
myomectomy to hysterectomy [10].
A number of interventions have been introduced to
reduce bleeding during myomectomy. Three categories of
interventions can be identified: (1) intervention on uterine
arteries such as laparoscopic uterine artery dissection,
uterine artery embolization, pericervical mechanical tour-
niquets, and hormonal tourniquets such as vasopressin and
telipressin; (2) uterotonics such as ergometrine, oxytocin,
misoprostol, and sulprostone; and (3) myoma dissection
techniques that include the use of laser and chemical
Fig. 3 Comparison of the change in the size of the myoma (A) before and (B) after misoprostol administration.
Color Doppler Misoprostol Response Study 81dissectors such as sodium mercaptoethanesulfonate
(mesna); however, the largest effect on blood loss during
myomectomy was recorded by the study that combined the
occlusion of the uterine arteries and ovarian arteries using
tourniquets prior to myoma enucleation. The uterus re-
ceives blood supply primarily from the uterine artery and
secondarily from the ovarian artery [11e15]. Misoprostol, a
prostaglandin E2 analogue, was equally shown to signifi-
cantly reduce blood loss, probably by causing uterine
contraction and reducing uterine blood flow [16].
Other interventions have not been able to demonstrate
the expected effect on blood loss that was theoretically
postulated. The trial on oxytocin, a known uterotonic
agent, showed no evidence of an effect on blood loss during
myomectomy. This is consistent with other evidence that
the myometrial concentration of oxytocin receptors is very
low in nonpregnant uteri [17].
The use of 800 mg of misoprostol per rectally has been
extensively studied in the obstetric patients and no serious
side effects have been reported. Similarly, in our study, no
serious side effects were observed. Only 2% of the patients
complained of lower abdominal pain, which can be attrib-
uted to the strong uterine contraction. Minor side effects
including pyrexia, shivering, nausea, and headache have
been reported in obstetric practice because of centrally
mediated prostaglandin E1 effects [18] and shivering
frequently following normal delivery; perhaps misoprostol
administration increases its incidence by lowering the
threshold for physiological shivering [19].
In a comparative study of r rectal versus oral adminis-
tration of misoprostol, it was found that the longer half of
rectally administered misoprostol could prolong uterineTable 1 Volume of fibroids (comparison within groups).
Volume of fibroids Mean  SD Mean
Group A
Baseline volume 423.4  287.9
At 20 min 383.1  264.4 t0e20
At 40 min 346.9  254.4 t20e4
Group B
Baseline volume 410.8  272.5
At 20 min 410.6  272.5 t0e20
At 40 min 417.3  272.5 t20e4
CI Z confidence interval; SD Z standard deviation.contraction compared to oral administration. Shivering and
pyrexia were both found to occur less often in the rectal
group. This effect could be caused by the lower peak serum
concentration and longer half-life of rectal misoprostol
compared to oral administration [19,20]. This was the basis
of our choice of the rectal route of administration of
misoprostol.
Misoprostol remains a very good option for reducing
blood flow in procedures such as hysteroscopic and lapa-
roscopic myomectomy whereby mechanical methods of
reducing blood flow cannot be applied [21,22].
The CDMRS in patients prior to and after insertion of
800 mg of misoprostal rectally showed significant reduction
in the blood flow of the segmental branch of the uterine
artery and those supplying fibroids. The change in Doppler
was seen either by elevated indices or no flow. Reduction in
the volume of the fibroid was also noted.
The reduction of flow and decrease in size may be
caused by the combined effect of myometrial contraction
and vasoconstrictive effect.
Almost all of the patients in our study showed a response
to misoprostol, where 50% of patients responded to miso-
prostol within 20 minutes and 90% responded within 40 mi-
nutes, which correlates with the peak serum concentration
of misoprostol following rectal administration [19].
It is also suggested that we need at least 40 minutes to
evaluate the maximum response to misoprostol in order to
complete the study.
A few patients, who did not respond to misoprostol as
observed by CDMRS, should be subjected to other means of
mechanical or chemical interventions depending on the
choice of the surgeon to reduce intraoperative blood loss.difference 95% CI p
Z 40.3 cm3 30.6e49.9 cm3 0.00
0 Z 36.2 cm
3 30.7e41.6 cm3 0.00
Z 0.2 cm3 1.69e0.99 0.08
0 Z 6.7 cm
3 14.64e3.28 0.21
Table 2 Resistance index (comparison within groups).
Resistance index Mean  SD Mean difference 95% CI p
Group A
Baseline RI 0.61  0.15
At 20 min 0.87  0.16 t0e20 Z 0.26 0.16e0.38 cm3 0.00
At 40 min 0.95  0.11 t20e40 Z 0.08 0.33e0.04 cm3 0.00
Group B
Baseline RI 0.60  0.17
At 20 min 0.61  0.17 t0e20 Z 0.01 0.004e0.001 0.267
At 40 min 0.60  0.17 t20e40 Z 0.00 0.005e0.008 0.584
CI Z confidence interval; RI Z resistance index; SD Z standard deviation.
82 M. Hasan et al.The reduction in the blood flow on CDMRS was based on
elevated indices, i.e., Pulstility Index (PI), RI, or no flow on
color Doppler.
All of the patients were asked to follow up after surgery;
however, because of the inconsistent timing of the sur-
geries, we received feedback on more than 20 patients and
their gynecologists gave a positive response. Our study was
limited to preoperative evaluation, therefore, this study
can be an initiative for the gynecologists to do a post-
operative study.
In conclusion, we firmly believe CDMRS may become an
important tool for preoperative risk assessment of myomas
for gynecologists planning myomectomy to use misoprostol
preoperatively and in so doing reduce the likelihood of
hemorrhage during surgery. We suggest that more ran-
domized studies be conducted to validate our findings.
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